Impact of Insulin Treatment on Prognosis of non-B non-C Hepatocellular Carcinoma After Hepatectomy

Anticancer Res. 2021 Jan;41(1):317-326. doi: 10.21873/anticanres.14778.

Abstract

Background/aim: Several studies have reported that DM is closely associated with an increased incidence of hepatocellular carcinoma (HCC). To clarify the effects of diabetes mellitus (DM) and antidiabetic medications on the prognosis of patients with non-B non-C (NBNC) HCC following curative initial hepatectomy.

Patients and methods: HCC patients (n=156) were divided into three groups according to the presence or absence of chronic viral hepatitis: hepatitis B virus (HBV) group, hepatitis C virus (HCV) group, and NBNC group. The clinical characteristics and survival outcomes were compared. In the NBNC group, univariate and multivariate analyses were conducted to determine prognostic factors.

Results: The NBNC group had a higher incidence of DM, ethanol intake, and large nodules than the other groups. Disease-free survival (DFS) was significantly worse in the NBNC group than in the HBV group. In the NBNC group, insulin treatment was an independent prognostic factor for DFS and overall survival (OS).

Conclusion: Medications for DM that affect insulin resistance might be appropriate prognostic factors for NBNC-HCC.

Keywords: HCC; diabetes mellitus; hepatectomy; insulin; prognosis.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Hepatocellular / complications*
  • Carcinoma, Hepatocellular / etiology
  • Carcinoma, Hepatocellular / mortality*
  • Carcinoma, Hepatocellular / surgery
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy*
  • Disease Susceptibility
  • Female
  • Hepatectomy
  • Humans
  • Insulins / administration & dosage*
  • Liver Neoplasms / complications*
  • Liver Neoplasms / etiology
  • Liver Neoplasms / mortality*
  • Liver Neoplasms / surgery
  • Male
  • Middle Aged
  • Postoperative Care*
  • Prognosis
  • Survival

Substances

  • Insulins